Regeneron Pharmaceuticals, Inc. (REGN) Stock Grade

About Regeneron Pharmaceuticals, Inc.'s fundamentals

Regeneron Pharmaceuticals is a large-cap biotechnology company with an $80.7 billion market capitalization that demonstrates strong profitability, with a net margin of 31.4% and return on equity of 14.4%. The company trades at a P/E ratio of 17.9, which is moderate relative to its profitability metrics. Revenue growth has slowed considerably, with year-over-year growth of just 1.0%, suggesting limited recent expansion. The company returns minimal capital to shareholders through dividends, with a yield of 0.5%, indicating a focus on retaining earnings.